ITMI20130403A1 - Anticorpi anti-bag3 per uso terapeutico - Google Patents

Anticorpi anti-bag3 per uso terapeutico

Info

Publication number
ITMI20130403A1
ITMI20130403A1 IT000403A ITMI20130403A ITMI20130403A1 IT MI20130403 A1 ITMI20130403 A1 IT MI20130403A1 IT 000403 A IT000403 A IT 000403A IT MI20130403 A ITMI20130403 A IT MI20130403A IT MI20130403 A1 ITMI20130403 A1 IT MI20130403A1
Authority
IT
Italy
Prior art keywords
antibody
bag3
use according
pharmaceutical composition
monoclonal antibody
Prior art date
Application number
IT000403A
Other languages
English (en)
Italian (it)
Inventor
Maria Caterina Turco
Original Assignee
Biouniversa Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa Srl filed Critical Biouniversa Srl
Priority to IT000403A priority Critical patent/ITMI20130403A1/it
Priority to KR1020157016521A priority patent/KR20150129649A/ko
Priority to CN201480003897.1A priority patent/CN104902927A/zh
Priority to JP2016503735A priority patent/JP6475225B2/ja
Priority to PCT/IB2014/059416 priority patent/WO2014147503A2/en
Priority to EP14716010.5A priority patent/EP2976104B1/en
Priority to ES14716010T priority patent/ES2721935T3/es
Priority to CA2895472A priority patent/CA2895472C/en
Priority to US14/651,213 priority patent/US20150329622A1/en
Publication of ITMI20130403A1 publication Critical patent/ITMI20130403A1/it
Priority to ES14830409.0T priority patent/ES2650942T3/es
Priority to US16/141,911 priority patent/US11117957B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Multiple-Way Valves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT000403A 2012-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico ITMI20130403A1 (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IT000403A ITMI20130403A1 (it) 2013-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico
EP14716010.5A EP2976104B1 (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use
CN201480003897.1A CN104902927A (zh) 2013-03-18 2014-03-04 用于治疗用途的抗-bag3抗体
JP2016503735A JP6475225B2 (ja) 2013-03-18 2014-03-04 治療上の使用のための抗ｂａｇ３抗体
PCT/IB2014/059416 WO2014147503A2 (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use
KR1020157016521A KR20150129649A (ko) 2013-03-18 2014-03-04 치료용 안티-bag3 항체들
ES14716010T ES2721935T3 (es) 2013-03-18 2014-03-04 Anticuerpos anti-BAG3 para uso terapéutico
CA2895472A CA2895472C (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use
US14/651,213 US20150329622A1 (en) 2012-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use
ES14830409.0T ES2650942T3 (es) 2013-03-18 2014-11-19 Válvula, en particular válvula de descarga de agua para inodoros
US16/141,911 US11117957B2 (en) 2012-03-18 2018-09-25 Anti-BAG3 antibodies for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000403A ITMI20130403A1 (it) 2013-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico

Publications (1)

Publication Number Publication Date
ITMI20130403A1 true ITMI20130403A1 (it) 2014-09-19

Family

ID=48227407

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000403A ITMI20130403A1 (it) 2012-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico

Country Status (9)

Country Link
US (2) US20150329622A1 (https=)
EP (1) EP2976104B1 (https=)
JP (1) JP6475225B2 (https=)
KR (1) KR20150129649A (https=)
CN (1) CN104902927A (https=)
CA (1) CA2895472C (https=)
ES (2) ES2721935T3 (https=)
IT (1) ITMI20130403A1 (https=)
WO (1) WO2014147503A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015019230A1 (en) 2013-08-07 2015-02-12 Biouniversa Srl Bag3 receptor binding molecules for use as a medicament

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
IT201600111877A1 (it) * 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
CN114533877B (zh) * 2022-03-09 2023-07-04 上海交通大学医学院附属第九人民医院 Bag3抑制剂在制备治疗瘢痕产品中的用途
WO2026074330A1 (en) 2024-10-01 2026-04-09 Fibrosys S.R.L. Antibodies and diagnostic methods for detecting bag3 protein in clinical samples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055908A2 (en) * 2001-12-28 2003-07-10 Arturo Leone Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2011067377A1 (en) * 2009-12-04 2011-06-09 Biouniversa S.R.L. Biochemical serum marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774355B2 (en) * 1998-09-09 2004-06-24 Burnham Institute, The Novel bag proteins and nucleic acid molecules encoding them
WO2009014759A2 (en) * 2007-07-25 2009-01-29 The Trustess Of Columbia University In The City Of New York Methods of inhibiting vzv replication and related compositions
EP2676966A1 (en) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 as biochemical serum and tissue marker

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055908A2 (en) * 2001-12-28 2003-07-10 Arturo Leone Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2011067377A1 (en) * 2009-12-04 2011-06-09 Biouniversa S.R.L. Biochemical serum marker

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A.FALCO: "Ruolo della proteina BAG3 nel micro ambiente tumorale", 2011, XP002714756, Retrieved from the Internet <URL:http://elea.unisa.it/jspui/bitstream/10556/293/1/tesi%20%20A.%20Falco.pdf> [retrieved on 20131014] *
MICHELINA FESTA ET AL: "BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy", AMERICAN JOURNAL OF PATHOLOGY; [10640], AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 178, no. 6, 1 June 2011 (2011-06-01), pages 2504 - 2512, XP002685427, ISSN: 0002-9440, [retrieved on 20110510], DOI: 10.1016/J.AJPATH.2011.02.002 *
ROSATI ALESSANDRA ET AL: "Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.", THE AMERICAN JOURNAL OF PATHOLOGY NOV 2012, vol. 181, no. 5, November 2012 (2012-11-01), pages 1524 - 1529, XP002714757, ISSN: 1525-2191 *
WANG HUA-QIN ET AL: "Characterization of BAG3 Cleavage During Apoptosis of Pancreatic Cancer Cells", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 224, no. 1, July 2010 (2010-07-01), pages 94 - 100, XP002714758, ISSN: 0021-9541 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015019230A1 (en) 2013-08-07 2015-02-12 Biouniversa Srl Bag3 receptor binding molecules for use as a medicament

Also Published As

Publication number Publication date
WO2014147503A3 (en) 2014-12-04
US20150329622A1 (en) 2015-11-19
CN104902927A (zh) 2015-09-09
JP2016516078A (ja) 2016-06-02
ES2650942T3 (es) 2018-01-23
WO2014147503A2 (en) 2014-09-25
JP6475225B2 (ja) 2019-02-27
ES2721935T3 (es) 2019-08-06
US20190010221A1 (en) 2019-01-10
CA2895472A1 (en) 2014-09-25
KR20150129649A (ko) 2015-11-20
EP2976104A2 (en) 2016-01-27
EP2976104B1 (en) 2019-01-30
US11117957B2 (en) 2021-09-14
CA2895472C (en) 2022-07-05

Similar Documents

Publication Publication Date Title
US11117957B2 (en) Anti-BAG3 antibodies for therapeutic use
CN111511765B (zh) 抗半乳凝素-9抗体及其用途
ES2784131T3 (es) Polipéptidos de unión beta del receptor PDGF
ES2378097T3 (es) Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
ES2673869T3 (es) Anticuerpos frente a ligandos del receptor B1 de bradicinina
US10793633B2 (en) Therapeutic peptides
ES3058239T3 (en) Multi-specific wnt surrogate molecules and uses thereof
JP6283411B2 (ja) Ｄｌｌ４とｖｅｇｆに特異的に結合する新規二重標的タンパク質とこれの用途
ES2818184T3 (es) Anticuerpo anti-Notch 4 humano
ES2724364T3 (es) Procedimiento de tratamiento de fibrosis pulmonar idiopática
RU2764993C2 (ru) Связывающие белки, специфичные в отношении lox1, и пути их применения
BR112020009707A2 (pt) anticorpos para a-sinucleína e usos dos mesmos
ES2808947T3 (es) Anticuerpos humanizados anti-BAG3
CN112996563A (zh) 靶向il-1r1和nlpr3的双特异性抗体
ES2731257T3 (es) Moléculas de unión al receptor de BAG3 para su uso como un medicamento
ES2913162T3 (es) Anticuerpo anti-Myl9
KR20220078568A (ko) Lrp5 단백질에 결합하는 항체 및 사용 방법
KR20220092859A (ko) 항-cxcr2 항체 및 이의 용도
BR112021002435A2 (pt) tratamento de câncer com um anticorpo
HK40073121B (zh) 抗trop-2抗体及其用途
HK40082759B (zh) 抗半乳凝素-9抗体及其用途
BR112017006609B1 (pt) Anticorpos isolados de receptor de lipoproteína de baixa densidade oxidada semelhante à lectina-1 (lox1), composição farmacêutica e usos de dita composição farmacêutica e anticorpos
KR20180101968A (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법